App
Psychedelics Production Challenges & Solutions
Ryan Allway December 21st, 2020 App, Exclusive, Psychedelics, Top News Psilocybin and other tryptamine-based compounds could become blockbuster therapeutics for the treatment of depression, post-traumatic stress disorder and other difficult to treat psychiatric conditions. While many clinical trials are underway, researchers are turning their attention toward the problem of... Read more
HempFusion Prepares to Go Public as a Unique Play on CBD
Ryan Allway December 18th, 2020 App, Exclusive, News, Top News Charlotte’s Web Holdings Inc. (TSX: CWEB) bought Abacus Health Products Inc. in a stock transaction worth about $100 million last June. With competition on the rise in the CBD industry, Abacus provided Charlotte’s Web with a portfolio of over-the-counter... Read more
Innovation Pays Off in Psychedelics
Ryan Allway December 18th, 2020 App, Exclusive, Psychedelics, Top Story There has been significant interest in the psychedelic space and of the promise psychedelic molecules show in treating mental health conditions. Mental illness is a ubiquitous human experience and an insufficiently addressed medical necessity. Psychedelics offer an alternative to... Read more
Pure Extracts Advances Plans for the Processing of Functional Mushroom Formulations
Ryan Allway November 26th, 2020 App, Psychedelics, Top News VANCOUVER, British Columbia, Nov. 26, 2020 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp . (CSE: PULL) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sectors, is pleased... Read more
Championing Female Representation in Canada’s Emerging Psychedelics Market
Ryan Allway November 25th, 2020 App, Psychedelics, Top News There is a global resurgence in the interest in psychedelics. With scientific, medical, and mental health communities revisiting its potential therapeutic benefits, psychedelics are being touted for its potential to treat addictions, mental health, cancer, amongst other ailments.  This year... Read more
Why Focus on Cannabis & Mushroom Extracts?
Ryan Allway November 25th, 2020 App, Exclusive, News, Top Story Cannabis extracts are poised to become a $28.5 billion market by 2027, according to Grand View Market Research, representing a 16.6% compound annual growth rate. At the same time, the functional mushroom market is forecast to reach $34.3 billion... Read more
How to Invest in the Rise of Cannabis-Infused Beverages
Ryan Allway November 18th, 2020 App, Exclusive, News, Top Story The cannabis industry has rapidly transitioned from an obscure counterculture movement to a legal industry that could exceed $27 billion by 2024, according to the MJBiz Daily. In addition to a growing number of states legalizing cannabis, the industry... Read more
HempFusion: A Health and Wellness Leader to IPO on the TSX Senior Board
Ryan Allway November 6th, 2020 App, Exclusive, News, Top Story Cannabidiol, better known as CBD, has become one of the fastest growing segments of the health and wellness industry. According to BDS Analytics and ArcView, CBD sales will grow at a 49% compound annual growth rate to exceed $20... Read more
ManifestSeven Doubles Revenue, Targets Profitability
Ryan Allway November 4th, 2020 App, Exclusive, News, Top News ManifestSeven Holdings Corporation (CSE: MSVN) recently reported third-quarter financial results that showed a 96% increase in year-over-year revenue and continued advancement towards net profitability. In particular, quarterly revenue rose 64% to $4.7 million and an adjusted EBITDA loss that... Read more
MagicMed Shortcuts Commercialization Timeline with University Agreement
Ryan Allway November 4th, 2020 App, Exclusive, Psychedelics, Top Story Most pharmaceutical and biotech investors are familiar with long commercialization timelines, but there are a few ways to shortcut the process. For example, the Food and Drug Administration provides Fast Track, Breakthrough Therapy, Accelerated Approval and Priority Review designations... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )